Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17102803 | 0.94 | ADRB2 (0.41) | ADRB2ADRB1ADRB3THRBDNM1 | |
| SCHEMBL3260445 | 0.90 | DNM1 (0.52) | THRBDNM1TSHRALDH1A1CA1 | |
| SCHEMBL4594523 | 0.88 | DNM1 (0.56) | THRBDNM1TSHRCA1CA2 | |
| SCHEMBL11101061 | 0.88 | DNM1 (0.56) | THRBDNM1TSHRCA1CA2 | |
| SCHEMBL6180238 | 0.88 | DNM1 (0.56) | THRBDNM1TSHRCA1CA2 | |
| SCHEMBL18240005 | 0.88 | DNM1 (0.56) | THRBDNM1TSHRCA1CA2 | |
| SCHEMBL7778179 | 0.88 | DNM1 (0.56) | THRBDNM1TSHRCA1CA2 | |
| SCHEMBL5159672 | 0.87 | TSHR (0.54) | ADRB2ADRB1ADRB3THRBDNM1 | |
| SCHEMBL3752173 | 0.83 | ADRB2 (0.38) | ADRB2ADRB1ADRB3THRBDNM1 | |
| SCHEMBL3752167 | 0.83 | ADRB2 (0.38) | ADRB2ADRB1ADRB3THRBDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 884 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250246673-A1 | LIQUID ADDITIVE WITH HIGH LITHIUM ION CONDUCTIVITY AND LOW REACTIVITY WITH SOLID ELECTROLYTE, AND ALL-SOLID-STATE BATTERY CAPABLE OF OPERATING AT ROOM TEMPERATURE AND LOW PRESSURE INCLUDING SAME | HYUNDAI MOTOR COMPANY (KR) | 2025-07-31 | — | — | US | claimed |
| WO-2025083450-A1 | INDUSTRIALLY BENIGN ONE-POT PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE AMITRAZ | HIKAL LIMITED (IN) | 2025-04-24 | — | — | WO | claimed |
| CN-119613414-A | Non-azolanet Process for the preparation of tam | 上海皓元医药股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-4452838-A1 | PROCESS FOR REMOVING WATER FROM BIS(FLUOROSULFONYL)IMIDE SOLUTIONS | SPECIALTY OPERATIONS FRANCE (FR) | 2024-10-30 | — | — | EP | claimed |
| CN-118745205-A | Preparation method of ursodeoxycholic acid and intermediate | 奥锐特药业股份有限公司 | 2024-10-08 | — | — | CN | claimed |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | ANHUI UNIVERSITY (CN) | 2024-08-13 | — | — | US | claimed |
| CN-118434672-A | Method for removing water from bis (fluorosulfonyl) imide solution | 法国特种经营公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | ANHUI UNIVERSITY (CN) | 2024-04-04 | — | — | US | claimed |
| CN-117164533-A | Method for synthesizing furylacetic acid compound by using carbon dioxide | 中国科学院兰州化学物理研究所 | 2023-12-05 | — | — | CN | claimed |
| CN-117142943-A | Method for synthesizing 6-hydroxycaproic acid (ester) by using carbon dioxide and furfuryl alcohol compounds | 中国科学院兰州化学物理研究所 | 2023-12-01 | — | — | CN | claimed |
| EP-1225172-A1 | POLYORTHOESTER AND CURABLE COMPOSITION CONTAINING THE SAME | KANSAI PAINT CO., LTD. (JP) | 2002-07-24 | — | — | EP | claimed |
| US-5760275-A | CATALYZING WITH CARBON MONOXIDE AND HYDROGEN IN PRESENCE OF GROUP 8 METAL COMPOUND | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1998-06-02 | — | — | US | claimed |
| EP-0307362-B1 | Process for the manufacture of aliphatylphosphinic acid derivatives | CIBA GEIGY AG (CH) | 1995-02-15 | — | — | EP | claimed |
| US-5030537-A | Photoconductive unsymmetrical squaraine compositions | XEROX CORPORATION (US) | 1991-07-09 | — | — | US | claimed |
| EP-0307362-A2 | Process for the manufacture of aliphatylphosphinic acid derivatives | CIBA-GEIGY AG (CH) | 1989-03-15 | — | — | EP | claimed |
| EP-0245938-A2 | Polymer composition | BP Chemicals Limited (GB) | 1987-11-19 | — | — | EP | claimed |
| WO-1987005916-A2 | POLYMER COMPOSITION | BP CHEMICALS LIMITED (GB) | 1987-10-08 | — | — | WO | claimed |
| US-4442277-A | COORDINATION CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1984-04-10 | — | — | US | claimed |
| US-4400303-A | REACTING MGCL2 WITH HALOGENATED TITANIUM COMPOUND | PHILLIPS PETROLEUM COMPANY (US) | 1983-08-23 | — | — | US | claimed |
| US-4258168-A | USING A TITANIUM HALIDE AND ALUMINUM ALKYL CATALYST AND ADDING ALKYL ORTHOFORMATES AND THIOPHOSPHORIC ACID ESTERS | STANDARD OIL COMPANY (INDIANA) (US) | 1981-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | TLR7, PON1, MYD88 | ADRB2 933/4885ADRB1 1261/4885ADRB3 1156/4885 |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | TLR7, PON1, MYD88 | ADRB2 934/4885ADRB1 1313/4885ADRB3 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.